Cuban Academy yeScience inogadzira mishonga yekudzivirira yekurapa isiri-diki cell cancer yemapapu- Vaxira uye CIMAvax. Iyi yazvino mhando yejekiseni inogona kurapa isiri-diki cell yemapapu cancer (NSCLC) yapinda chikamu 3 chekiriniki yekusimbisa uye ine mhedzisiro yakanaka kune isiri-diki cell cancer yemapapu. Iko zvino yapinda mumakiriniki ekukumbira mukati Kiyuba uye Peru. Mhedzisiro yetsvagurudzo iyi inofadza yakagonesa aimbova Mutungamiriri weUS Barack Obama kusimudzira chirango chemakore makumi mashanu nemashanu mushure mekushanya Kiyuba, and introduced the latest anti-cancer technology to the United States in 2015. The US Food and Drug Administration (FDA) has approved the United States to conduct a clinical trial of a lung cancer vaccine developed in Cuba, which can stimulate the lung cancer patient’s own immune system.
Chii chinonzi CIMAvax?
CIMAvax-EGF is a kenza yemapapu treatment that was developed in Cuba. It is a type of immunotherapy that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced isina-diki kenza yemapapu kenza (NSCLC).
CIMAvax inoshanda sei?
Yakagadzirwa nevatsvagiri paCentre for Molecular Immunology (CIM) muHavana, Cuba, CIMAvax-EGF inovhara rudzi rweprotein - epidermal growth factor (EGF) - iyo masero egomarara anofanirwa kukura. Iyo haiurayi masero zvakananga, masero ane kenza kana neimwe nzira, asi "ane nzara" iwo nekudzivirira EGF kubva pakubatanidza kune yayo yakakodzera receptor (EGFR) pasero. Kubatana uku kunodiwa kuti sero rikure uye riwande. Pasina iyo, sero regomarara hariwande, uye rinofa. CIMAvax inovhara EGF nekushandisa mhinduro yemurwere.
"Carrier protein" muCIMAvax inokonzeresa immune system kuti ibudise masoja anorwisa epuroteni yeEGF kuti ishandise. Izvi zvinopedza kutenderera EGF kubva muropa, zvichinyima maseru ekenza eiyi kiyi yakakosha mukukura uye kurarama.
More than 5,000 lung cancer patients have been treated with this unique immunotherapy, and several international studies have indicated prolonged tumarara stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay and Peru.
Chii chinonzi Vaxira?
Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.
Racotumomab inorwisa anti-idiotypic monoclonal antibody iyo inokonzeresa muvarwere simba rekuzvidzivirira kubva kune chaiwo glycolylated gangliosides (NeuGcGM3) aripo mumatumbu maseru. Vaxira® inowedzera kupona kwevarwere veNSCLC mumatanho anodzokororwa kana epamberi (IIIB / IV) zvichienzaniswa nechengetedzo yepamusoro. Vaxira® inoregererwa zvakanaka uye chimiro chayo chekuchengetedza chinogamuchirwa. Zviitiko zvakajairika zvakajairika zvinowanikwa munharaunda (panzvimbo yekutonga), zvinyoro uye zvinopera.
Kunyangwe ivo varwere vakabayiwa majekiseni eVaxira® mushure mekurwara kwechirwere chavo varatidza kuvandudzwa mukupona kwese.
Kugadzirisa: Imwe vial yeVAXIRA® ine: mAb Racotumomab 1.00 mg, aluminium hydroxide [Al (OH) 3] 5.00 mg, tris (hydroxymethyl) aminomethane 12.14 mg, sodium chloride 3.40 mg, mvura yejekiseni qs 1.0 ml. Vaxira® inorwisa mishonga inodzivirira anti-idiotypic monoclonal antibody Racotumomab uye aluminium hydroxide (AH), anoshandiswa zvakanyanya adjuvant. AH inowedzera kugadzirwa kwemasoja ekudzivirira chirwere, asi haisi immunogenic kana hapten. Inozvibata senzvimbo yekuchengetera panzvimbo yejekiseni panoburitswa antigen zvishoma uye, panguva imwechete, inokonzeresa kuumbwa kwema granulomas anokwezva maseru anokwanisa kukwana akadai semasero-eplasma-anogadzira masero eplasma. AH inogona kukurudzira zvakananga monocyte kuburitsa proinfigueatory cytokines iyo inogona kumisikidza T maseru, uye inogona zvakare kukurudzira iyo B cell kupindura.
Ungatenga sei CIMAvax uye Vaxira muIndia?
CIMAvax and Vaxira at present are not available in India. These vaccines need to be ordered for personalized treatment. To order the medicine please WhatsApp patient details to + 91 96 1588 1588.
